Status:

WITHDRAWN

Tadalafil-Delivra and Raynaud's Phenomenon

Lead Sponsor:

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Collaborating Sponsors:

Delivra, Inc.

Conditions:

Raynaud Phenomenon

Eligibility:

All Genders

18-75 years

Brief Summary

A 4-8 week observational feasibility study of the use of the use of Tadalafil-Delivra in the treatment of Reynaud's Phenomena (RP).

Detailed Description

To determine if the feasibility of conducting a future RCT using the chosen outcome assessments in RP patients at 2 Rheumatology clinics. Study Design: Observation of patients prescribed Tadalafil-D...

Eligibility Criteria

Inclusion

  • Adults of both genders, Age 18 to 75 years.
  • Patients with a confirmed diagnosis of Raynaud's Phenomenon (RP).
  • Written informed consent.
  • The presence of 1 or more digital ulcers (DU), that is not related to calcinosis, anywhere on a finger that is symptomatic for RP- defined as a VAS pain score of ≥25mm of 100mm Or 1 -3 fingers that are symptomatic for RP under standard of care treatment (SoC). Symptomatic is defined as a VAS pain score of ≥ 25mm of 100mm.
  • Prescribed, but not currently being treated with Tad-Del.
  • Maintenance of a stable background of prescribed treatment for RP including vasodilators, orally administered PDE5i and pain medication. Changes to administration of this concomitant medication will be documented in the case report form (CRF).

Exclusion

  • Unwilling and/or incapable of adhering to the study procedures and follow-up schedule.
  • Use of other prescribed topical treatment for RP, such as nitrates.
  • Active infection of the index ulcer
  • Calcinosis at the site of the index ulcer
  • Received Iloprost or other prostacyclin treatment in the last 4 months.
  • Unsuitable for study participation as determined by the clinical investigator.

Key Trial Info

Start Date :

October 1 2018

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 1 2019

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT03393325

Start Date

October 1 2018

End Date

September 1 2019

Last Update

September 20 2018

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

St. Joseph's Healthcare

Hamilton, Ontario, Canada, L8N 4A6

2

Mount Sinai Hospital

Toronto, Ontario, Canada, M5T3L9